Information:
Fel:
ID
13286
Beskrivning
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00211133
Länk
https://clinicaltrials.gov/show/NCT00211133
Nyckelord
Versioner (1)
- 2016-01-31 2016-01-31 -
Uppladdad den
31 januari 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Anemia NCT00211133
Eligibility Anemia NCT00211133
- StudyEvent: Eligibility
Similar models
Eligibility Anemia NCT00211133
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Participants
Item
female patients >= 18 years of age with confirmed diagnosis of metastatic breast cancer who are predicted to start chemotherapy for the first time
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0346993 (UMLS CUI [3])
C0392920 (UMLS CUI [4])
C0001779 (UMLS CUI [2])
C0346993 (UMLS CUI [3])
C0392920 (UMLS CUI [4])
Body Weight
Item
weight > = 40 kg (88 lbs)
boolean
C0005910 (UMLS CUI [1])
gynaecological status
Item
postmenopausal for at least 1 year, surgically sterile or practicing an effective method of birth control and have a negative serum pregnancy test at the start of the study
boolean
C0232970 (UMLS CUI [1])
C0015787 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
C0032976 (UMLS CUI [4])
C0015787 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
C0032976 (UMLS CUI [4])
informed consent
Item
must have signed an informed consent
boolean
C0021430 (UMLS CUI [1])
Comorbidity
Item
clinically significant lung, heart, hormone, neurological, gastrointestinal, urinary tract or reproductive system disease
boolean
C0024115 (UMLS CUI [1])
C0018799 (UMLS CUI [2])
C0014130 (UMLS CUI [3])
C0027765 (UMLS CUI [4])
C0017178 (UMLS CUI [5])
C0042075 (UMLS CUI [6])
C0178829 (UMLS CUI [7])
C0018799 (UMLS CUI [2])
C0014130 (UMLS CUI [3])
C0027765 (UMLS CUI [4])
C0017178 (UMLS CUI [5])
C0042075 (UMLS CUI [6])
C0178829 (UMLS CUI [7])
dose intensification chemotherapy
Item
receiving dose intensification chemotherapy for bone marrow or stem cell transplantation
boolean
C0149710 (UMLS CUI [1])
Malignancy
Item
cancer of the brain or brain/spinal cord disease
boolean
C0153633 (UMLS CUI [1])
C0153646 (UMLS CUI [2])
C0153646 (UMLS CUI [2])
Symtoms of breast cancer
Item
locally advanced or inflammatory breast cancer as the only symptom of breast cancer
boolean
C3495949 (UMLS CUI [1])
C0278601 (UMLS CUI [2])
C0278601 (UMLS CUI [2])
malignancy
Item
active second primary cancer or documented history of other cancer within the last 3 years
boolean
C0751623 (UMLS CUI [1])
C2735088 (UMLS CUI [2])
C2735088 (UMLS CUI [2])
anaemia
Item
anemia from a cause other than cancer or radiotherapy/chemotherapy
boolean
C0002871 (UMLS CUI [1])
Coaguation status
Item
history of stoke, clots in the lungs or legs or any other blood clotting disorders
boolean
C0038454 (UMLS CUI [1])
C0034065 (UMLS CUI [2])
C0151618 (UMLS CUI [3])
C0005779 (UMLS CUI [4])
C0034065 (UMLS CUI [2])
C0151618 (UMLS CUI [3])
C0005779 (UMLS CUI [4])
Blood pressure
Item
uncontrolled high blood pressure
boolean
C0005823 (UMLS CUI [1])
folate/ Vitamin b12 status
Item
untreated folate or vitamin b12 deficiency
boolean
C0523631 (UMLS CUI [1])
C0202252 (UMLS CUI [2])
C0202252 (UMLS CUI [2])
erythropoietin treatment
Item
treatment with epoetin alfa or other forms of erythropoietin within the last 4 weeks
boolean
C0376541 (UMLS CUI [1])
Allergy
Item
known hypersensitivity to epoetin alfa or any of its components
boolean
C0020517 (UMLS CUI [1,1])
C0357126 (UMLS CUI [1,2])
C0357126 (UMLS CUI [1,2])
gynaecological status
Item
pregnant or breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])